In the article by Ott et al, the aim of the study, KEYNOTE-028 (NCT02054806), was to evaluate the activity and safety profile of pembrolizumab in patients with heavily pretreated advanced endometrial cancer (EC), a subgroup with a poor prognosis. This article deserves some consideration to give the study proper meaning. Unfortunately, it is a small study, as are others that explore the activity of different agents in advanced and metastatic EC.
Pembrolizumab in programmed death ligand 1-positive endometrial cancer / Tomao, Federica; BENEDETTI PANICI, Pierluigi; Tomao, Silverio. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 35:31(2017), pp. 3633-3633. [10.1200/JCO.2017.74.4987]
Pembrolizumab in programmed death ligand 1-positive endometrial cancer
Federica Tomao
Primo
;Pierluigi Benedetti PaniciPenultimo
;Silverio TomaoUltimo
2017
Abstract
In the article by Ott et al, the aim of the study, KEYNOTE-028 (NCT02054806), was to evaluate the activity and safety profile of pembrolizumab in patients with heavily pretreated advanced endometrial cancer (EC), a subgroup with a poor prognosis. This article deserves some consideration to give the study proper meaning. Unfortunately, it is a small study, as are others that explore the activity of different agents in advanced and metastatic EC.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tomao_Pembrolizumab _2017.pdf
accesso aperto
Note: https://ascopubs.org/doi/pdf/10.1200/JCO.2017.74.4987
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
427.36 kB
Formato
Adobe PDF
|
427.36 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
